RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model
dc.contributor.author | Ignatoski, Kathleen M. Woods | en_US |
dc.contributor.author | Escara-Wilke, June | en_US |
dc.contributor.author | Dai, Jinlu | en_US |
dc.contributor.author | Lui, A. | en_US |
dc.contributor.author | Dougall, William C. | en_US |
dc.contributor.author | Daignault, Stephanie D. | en_US |
dc.contributor.author | Yao, Zhi | en_US |
dc.contributor.author | Zhang, J. | en_US |
dc.contributor.author | Day, Mark L. | en_US |
dc.contributor.author | Sargent, E. E. | en_US |
dc.contributor.author | Keller, Evan T. | en_US |
dc.date.accessioned | 2008-05-12T13:37:02Z | |
dc.date.available | 2009-06-01T20:08:52Z | en_US |
dc.date.issued | 2008-06-01 | en_US |
dc.identifier.citation | Ignatoski, K. M. Woods; Escara-Wilke, J. F.; Dai, J.-L.; Lui, A.; Dougall, W.; Daignault, S.; Yao, Z.; Zhang, J.; Day, M. L.; Sargent, E. E.; Keller, E. T. (2008). "RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model." The Prostate 68(8): 820-829. <http://hdl.handle.net/2027.42/58561> | en_US |
dc.identifier.issn | 0270-4137 | en_US |
dc.identifier.issn | 1097-0045 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58561 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18324676&dopt=citation | en_US |
dc.description.abstract | BACKGROUND Docetaxel induces an anti-tumor response in men with advanced prostate cancer (PCa); however, the side effects associated with docetaxel treatment can be severe, resulting in discontinuation of therapy. Thus, identification of an effective adjuvant therapy to allow lower doses of docetaxel is needed. Advanced PCa is typically accompanied by skeletal metastasis. Receptor activator of NFkB ligand (RANKL) is a key pro-osteoclastic factor. Targeting RANKL decreases establishment and progression of PCa growth in bone in murine models. METHODS The efficacy of inhibiting RANKL, using a recombinant soluble RANK extracellular domain fused with the immunoglobulin Fc domain (RANK-Fc), was tested as an adjuvant therapy with docetaxel for PCa bone metastasis in a murine intra-tibial model. RESULT The combination of RANK-Fc and docetaxel reduced tumor burden in bone greater than either treatment alone. CONCLUSION The combination of docetaxel with a RANKL-inhibiting agent merits further investigation for treatment of advance PCa. Prostate 68:820–829, 2008. © 2008 Wiley-Liss, Inc. | en_US |
dc.format.extent | 373095 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan Cancer Center Biostatistics Core, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan Health Systems, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan ; Department of Urology, University of Michigan Medical School, 5111 CCC, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0940. | en_US |
dc.contributor.affiliationother | Amgen, Seattle, Washington | en_US |
dc.contributor.affiliationother | Department of Immunology, Tianjin Medical University, Tianjin, China | en_US |
dc.contributor.affiliationother | Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania | en_US |
dc.identifier.pmid | 18324676 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58561/1/20744_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/pros.20744 | en_US |
dc.identifier.source | The Prostate | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.